Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people
around the world. The two main pathological mechanisms underlying the disease are beta …

In recent years, significant advancements have been made in understanding Alzheimer's
disease from both neurobiological and clinical perspectives. Exploring the complex systems …

Several studies investigating the pathogenesis of Alzheimer's disease have identified
various interdependent constituents contributing to the exacerbation of the disease …

Introduction In the last 15 years, huge efforts against Alzheimer's disease (AD) with drugs
targeting β-amyloid (Aβ) and tau have produced poor clinical results. Aducanumab, a …

Currently, of the few accessible symptomatic therapies for Alzheimer's disease (AD),
memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the …

Dementia, and in particular Alzheimer's disease (AD), can be characterized by disrupted
functional connectivity in the brain caused by beta-amyloid deposition in neural links. Non …

Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that
affect millions of individuals and have notoriously limited treatment options. One emerging …

Abstract Background Recent studies propose 40 Hz neural activity induction as a promising
approach for managing Alzheimer's dementia (AD). However, traditional flickering light is …

Alzheimer disease (AD) is a neurodegenerative disorder that primarily affects older adults
and is the most common cause of dementia. The most essential and often earliest clinical …

Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA,
was approved using the less common accelerated approval pathway by the Federal Drug …